Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paratek Pharmaceuticals, Inc.

http://paratekpharma.com/

Latest From Paratek Pharmaceuticals, Inc.

Pfizer Triples Down On CDK Inhibition In Breast, Other Cancers

Pfizer is looking to address breast cancer resistant to Ibrance and other CDK4/6 inhibitors, but sees potential paths to earlier lines of treatment and additional tumors.

Research and Development Strategies Cancer

Deal Watch: Artios Links Up With Novartis On DNA Damage Response Modifiers

Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.

Deals Business Strategies

MSN Deals Out Of Movantik But Two ANDA Filers Remain

India’s MSN Laboratories is set to move on a generic version of RedHill Biopharma’s Movantik (naloxegol oxalate) for opioid-induced constipation ahead of patent expiry under the terms of a patent-litigation settlement agreement.

Intellectual Property Deals

Finance Watch: DRI Healthcare’s Canadian IPO Enables More Royalty Deals

Public Company Edition: US initial public offerings are reawakening from a brief nap as Prometheus and Longboard prepare IPOs for launch. Also, Halozyme sells $700m worth of notes and Karuna’s $250m stock sale leads recent follow-on offerings.

Financing Growth
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Novacea, Inc.
    • Transcept Pharmaceuticals, Inc.
    • TransOral Pharmaceuticals, Inc.
UsernamePublicRestriction

Register